Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of BRAFV600E and TERT Promoter Mutations on Thyroglobulin Response in Patients With Distant-Metastatic Differentiated Thyroid Cancer.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists - 1 Mar 2022

Mu Zhuan-Zhuan, Zhang Ying-Qiang, Sun Di, Lu Tao, Lin Yan-Song

Abstract excerpt

OBJECTIVE: To assess the impact of serine/threonine-protein kinase B-Raf (BRAF) V600E and telomerase reverse transcriptase (TERT) promoter mutations in patients with distant-metastatic differentiated thyroid cancer (DM-DTC) based on thyroglobulin (Tg) response to radioactive iodine (RAI) therapy. METHODS: The BRAFV600E and TERT mutations in primary tumors or metastatic lymph nodes of 114 patients with DM-DTC were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Iodine Radioisotopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Telomerase

Share to Thyroglobulin

Share to Thyroid Cancer Diagnosis and Treatment

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 34890787
DOI: 10.1016/j.eprac.2021.12.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of BRAFV600E and TERT Promoter Mutations on Thyroglobulin Response in Patients With Distant-Metastatic Differentiated Thyroid Cancer.PMID 34890787Read ↗

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.Semantic proximity Read ↗

The Correlation Between the Presence of BRAFV600E and TERT Promoter Mutation and the Response to Treatment with Iodine 131 in Differentiated Thyroid Cancer Patients.Semantic proximity Read ↗

Clinical Outcome and Prognosis of Differentiated Thyroid Carcinoma with Distant MetastasisSemantic proximity Read ↗

TERT Promoter Mutations Contribute to Adverse Clinical Outcomes and Poor Prognosis in Radioiodine Refractory Differentiated Thyroid CancerSemantic proximity Read ↗

TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.Semantic proximity Read ↗

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.Semantic proximity Read ↗

Risk-stratified Distant Metastatic Thyroid Cancer with Clinicopathological Factors and BRAF/TERT Promoter Mutations.Semantic proximity Read ↗

Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.Semantic proximity Read ↗

Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.Semantic proximity Read ↗

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.Semantic proximity Read ↗

How do BRAFV600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?Semantic proximity Read ↗

Efficacy of Radioiodine in Non-Distant Metastatic Papillary Thyroid Cancer with TERT-p Mutation at Initial DiagnosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.